September 8, 2017
BMS buys IFM Therapeutics
Bristol-Myers Squibb has completed its previously announced acquisition of IFM Therapeutics, the company said on Thursday.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: IFM Therapeutics
August 4, 2017
Bristol-Myers Squibb strengthens its oncology pipeline – buys IFM Therapeutics
Bristol-Myers Squibb and IFM Therapeutics have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders.